Scarica l'app Stockscreener
25.80
0.54%
-0.14
Dopo l'orario di chiusura:
25.80
Zymeworks Inc. Borsa (ZYME) Ultime notizie
ZYME PE Ratio & Valuation, Is ZYME Overvalued - Intellectia AI
ZYME Technical Analysis & Stock Price Forecast - Intellectia AI
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Inc. R (ZA8.DU) Q1 FY2025 earnings call transcript - Yahoo Finance
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Trade Report: How sensitive is Zymeworks Inc to inflationMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
ZymeworksLeveraging Partnerships For Value - RTTNews
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Singapore
Trade Recap: Can Zymeworks Inc grow without dilution2026 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Zymeworks appoints Kristin Stafford as chief financial officer By Investing.com - Investing.com Australia
Zymeworks appoints Kristin Stafford as CFO - msn.com
Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026 - MarketScreener
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - wahanariau.com
Zymeworks Names Kristin Stafford as New Chief Financial Officer - TipRanks
Zymeworks Appoints Kristin Stafford as Chief Financial Officer to Drive Strategic Growth and Value Creation - Minichart
Zymeworks appoints Kristin Stafford as chief financial officer - Investing.com
Kristin Stafford named Zymeworks executive VP and CFO as Kenneth Galbraith steps down as interim CFO - TradingView
Kristin Stafford joins Zymeworks (Nasdaq: ZYME) as new Chief Financial Officer - Stock Titan
Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks - Stock Titan
How Investors May Respond To Zymeworks (ZYME) Fast Track Nod For Ovarian Cancer ADC ZW191 - Yahoo Finance
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer By Investing.com - Investing.com South Africa
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer - Investing.com Australia
Investment Report: Will Zymeworks Inc benefit from geopolitical trendsPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
Zymeworks Inc Receives U S Fda Fast Track Designation for Zw191 an Fra Targeting Antibody Drug Conjugate - MarketScreener
Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191 - TipRanks
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - ChartMill
Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)? - simplywall.st
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN
Assenagon Asset Management S.A. Sells 679,400 Shares of Zymeworks Inc. $ZYME - marketbeat.com
A Look At Zymeworks (ZYME) Valuation As New AACR ADC Data Advances Its Cancer Pipeline - Sahm
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Zymeworks Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Zymeworks Announces Participation in Upcoming Investor Conferences - Sahm
Aug Weekly: Does Zymeworks Inc stock have upside surprise potentialGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences - TipRanks
Published on: 2026-03-23 15:16:44 - baoquankhu1.vn
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Inc stock faces biotech volatility amid pipeline updates and market shifts - AD HOC NEWS
Will Zymeworks Inc benefit from rising consumer demand2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - GlobeNewswire
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - Koreabizwire
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com Australia
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting - Bitget
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Prosight Management LP Cuts Stake in Zymeworks Inc. $ZYME - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):